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Abstract
Background We examined skin autofluorescence (sAF) in
chronic kidney disease children (CKD) in relation to renal
function and dialysis modality.
Methods Twenty children on hemodialysis (HD), 20 on
peritoneal dialysis (PD), 36 treated conservatively, and 26
healthy subjects were enrolled into the study. In all children
sAF, pulse-wave velocity indexed to height (PWV/ht), left
ventricular mass index (LVMI), blood pressure (BP), serum
lipid profile, phosphate (P), calcium (Ca), and homocysteine
were measured.
Results sAF was significantly elevated in CKD groups vs.
controls and was significantly associated with PWV/ht,
LVMI, BP, P, Ca × P product and homocysteine. sAF in
HD and PD groups was positively correlated with dialysis
vintage, and in the predialysis group negatively correlated
with glomerular filtration rate (eGFR). Multiple regression
analysis showed significant association of sAF with LVMI
and P in the CKD patient group, and with dialysis treatment
duration and BP in dialyzed children.
Conclusions In CKD children, tissue accumulation of ad-
vanced glycation end-products (AGEs) was observed. This
was aggravated as eGFR declined and was related to early
cardiovascular changes and some biochemical cardiovascular
disease (CVD) risk markers. sAF as a non-invasive method
may be a useful tool for identification of a clinical risk factors
of cardiovascular disease in CKD children.
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Introduction
Cardiovascular disturbances are identified as the most seri-
ous complications in patients with chronic kidney disease
(CKD) [1]. They lead to increased morbidity and mortality
as compared to the general population. In particular, the
patients on dialysis experience the highest risk of death [2,
3]. It has been recently established that advanced glycation
end-products (AGEs) may contribute to vascular damage in
addition to classical mechanisms [4]. AGEs are formed and
accumulate in response to carbonyl and oxidative stress and
decreased kidney excretion of AGEs precursors [5, 6]. Data
from the literature show that in CKD patients, oxidative
stress is increased, even at early stages [7]. The uremic
toxins and modalities of renal replacement therapy enhance
oxidative stress and lead to higher formation of AGEs [8, 9].
AGEs accumulate mainly in the extracellular matrix causing
the alteration of functional properties of structural molecules
such as collagen, which induces arterial or cardiac damage
[10]. AGEs contribute to endothelial dysfunction by increas-
ing vascular deposition of oxidized low-density lipopro-
teins, reducing nitric oxide concentration, enhancing
oxidative stress, and causing abundant macrophage migra-
tion [11]. The interaction between AGEs and their receptors
(RAGEs) induces the synthesis of proinflammatory cyto-
kines subsequently leading to vascular damage. RAGEs are
expressed on different cells, but endothelial RAGE has been
indicated as the key factor for endothelial dysfunction [12,
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13]. It should be emphasized that plasma levels of AGEs do
not reflect tissue accumulation and, in contrast to tissue AGEs,
are not predictive for cardiovascular morbidity and diastolic
function deterioration [14, 15]. Until recently, determination
of tissue AGEs was exclusively based on skin biopsy exam-
ination. Since the last few years, a new noninvasive optical
tool, the autofluorescence reader, has given the opportunity to
measure skin autofluorescence (sAF), which has proved to be
well correlated with skin AGEs accumulation [16].
sAF was found to be related to age, smoking, diabetic
status, and its complications in adult patients [17]. Elevated
skin autofluorescence has been documented in patients with
stable coronary artery disease, acute myocardial infarction
[18] and in hemodialyzed adults with increased arterial stiff-
ness [8]. Skin AF has been shown to be a predictive factor for
morbidity and mortality evaluation in diabetic patients with
end stage renal disease (ESRD) [19, 20]. Recently, data
presented by Hartog et al. confirmed that sAF is an indepen-
dent predictor of graft loss in kidney transplant recipients
[21]. To date, sAF measurements in children have not been
applied as a diagnostic procedure. We hypothesize that, as in
the adult population, sAF might be associated with biochem-
ical and morphologic abnormalities related to cardiovascular
status in CKD children. Therefore, we investigated, for the
first time, whether sAF varies in children with CKD, includ-
ing stage 5 patients. We also analyzed the association of sAF
with arterial stiffness, left ventricular mass index, and other
risk factors for cardiovascular disease (CVD). In CKD
patients, the impact of CKD stage and duration of renal
replacement therapy on sAF were examined.
Patients and methods
This is a cross-sectional multicenter study. Seventy-six chil-
dren with CKD were included in examinations. The patients
were divided into three groups. Twenty-six age-matched
healthy children served as controls. Clinical and demo-
graphic details of the study subjects are summarized in
Table 1. The first group (PD) included 20 children on
peritoneal dialysis. Night intermittent peritoneal dialysis
(NIPD) was performed in 12 patients and continuous cyclic
peritoneal dialysis (CCPD) in eight patients. The Home-
Choice device was used (Baxter International, Inc, IL,
USA). Standard dialysis solutions with 1.5 % and 2.3 %
glucose concentrations and 1.25 mmol/l or 1.75 mmol/l cal-
cium concentrations were applied. The causes of CKD in
this group were: urinary tract abnormalities (6), glomerulo-
nephritis (5), polycystic kidney disease (3), neurogenic
bladder (3), hereditary nephropathy (2), and hemolytic ure-
mic syndrome (1). Thirteen children received angiotensin-
converting enzyme inhibitors (ACE-i), six received calcium
channel blockers, and three received β-blockers. All the
subjects received calcium-containing phosphate binders, vi-
tamin D analogs, and erythropoietin.
The second group (HD) consisted of 20 children on
hemodialysis. Dialysis sessions were performed three times
a week (3–5 h) with polysulfone membranes. The blood
flow ranged from 120 to 250 ml/min, and dialysate flow
500 ml/min. Dialysis fluid was buffered with bicarbonate
and calcium content was 1.25 or 1.5 mmol/l. All children
received heparin. The causes of CKD in this group were:
Table 1 Clinical and biochemi-
cal characteristics of investigated
chronic kidney disease (CKD)
groups and controls (two-by-two
comparison, p values are shown)
PD peritoneal dialysis, HD
hemodialysis
aPD, HD, Pre vs. control group
bHD, Pre vs. PD
cPD, Pre vs. HD
dPD, HD vs. Pre
Group Parameter PD, n020 HD, n020 Pre, n036 Controls, n026 p value
Age (year) 14.3±2.3 15±3.3 14.9±3.5 14.5±3.3 NS
Gender (m/w) 12/8 10/10 17/19 12/14 NS
Dialysis vintage
(months)
12±11 19±16 – – p00.02
BMI (kg/m2) 18.7±3.9 18.7±3.4 20.6±4.1 18.8±3.9 NS
SBP (mmHg) 117±11a,c 128±13a,b,d 115±10a 100±9 p < 0.0001
DBP (mmHg) 75±11a,c 82±10a,b,d 71±8a 64±6 p < 0.0001
Creatinine (mg/dl) 6.3±2.6a,d 7.6±3.4a,d 2.5±1.6a,b,c 0.68±0.11 p < 0.0001
Total cholesterol
(mg/dl)
206±43a 174±33 203±100a 162±13 p00.0001
LDL cholesterol
(mg/dl)
143±44a,c,d 92±31b 105±69b 84±6.2 p < 0.0001
HDL cholesterol
(mg/dl)
52±15 46±9 50±10 49±4 NS
TGL (mg/dl) 179±75a 166±59 187±242a 86±6.5 p < 0.0001
Ca (mg/dl) 9.71±0.79c 9.23±0.56a,b,d 9.69±0.63a,c 9.99±0.34 p00.0002
P (mg/dl) 5.48±1.81a,c,d 6.32±1.17a,b,d 4.52±0.97b,c 4.45±0.54 p < 0.0001
Ca x P (mg2/dl2) 53.5±19.4a,d 58.1±10a,d 43.6±8.9b,c 44.3±5.3 p < 0.0001
CRP (mg/l) 2.97±0.453 3.64±0.98a,b 3.3±0.65 2.5±0.15 p < 0.0001
iPTH (pg/ml) 206±177a,c 444±524a,b,d 138±135c 30.7±4 p < 0.0001
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urinary tract abnormalities (8), glomerulonephritis (6), neu-
rogenic bladder (4), hereditary glomerulopathy (2). Nine-
teen children were treated with ACEi, 11 with calcium
channel blockers, 2 with β-blockers. All the patients re-
ceived calcium-containing phosphate binders, vitamin D
analogs, and erythropoietin.
The third group (Pre) included 36 children with 2–4 stage
CKD on conservative treatment. The causes of CKD were:
urinary tract malformations (22), glomerulonephritis (5),
polycystic kidney disease (3), hereditary glomerulopathy
(2), unknown cause (2), hemolytic uremic syndrome (1),
complications after chemotherapy of cancer (1). CKD stage
2 was detected in 13 children, stage 3 in 10, and stage 4 in
13 patients. Twelve subjects were treated with ACE-i, six
with angiotensin receptor blockers (ARB), four calcium
channel blockers, and one child with a β-blocker.
All patients with CKD stage 2–4 received treatment with
calcium-containing phosphate binders, vitamin D analogs,
and ten in stage 4 received erythropoietin.
Children below the age of six were excluded from the
study. None of the children suffered from diabetes. During
the examination period, children had no signs of infection.
Patients with recent peritonitis or line infections were
excluded.
Informed consent for participation in the study was
obtained from all parents, and from children over 15. The
research project was approved by the Wroclaw Medical
University Ethics Committee.
CKD classification was based on K/DOQI guidelines
from 2002 [22]. Estimated glomerular filtration rate (GFR)
was determined with the Schwartz formula [23]. In all
children, laboratory tests were performed and blood pres-
sure (BP), pulse wave velocity (PWV), sAF, and left ven-
tricular mass (LVM) measurements were recorded. Left
ventricular mass index (LVMI) was calculated.
Blood samples obtained after overnight fasting were
drawn from the peripheral vein in PD patients, Pre patients
and the control group, and in hemodialyzed children prior to
starting an HD session. Biochemical parameters: serum
creatinine, total cholesterol, HDL-cholesterol, LDL-
cholesterol, triglycerides (TGL), calcium (Ca), phosphate
(P) concentration and Ca × P product were measured using
a multichannel analyzer KONELAB30i (THERMO, Bio
Merieux, France). Intact parathormone (iPTH) was mea-
sured using IRMA kit Duo PTH (Scantibodies Laboratory
Inc, CA, USA). BMI was calculated as weight in kilograms
divided by height in meters squared.
Blood pressure measurements with the oscillometric de-
vice were performed according to the recommendations
from the fourth Report of the Blood Pressure Control in
Children Working Group [24].
Pulse wave velocity (PWV) measurements were per-
formed in the supine position after a 10-min bed rest on
the carotid and femoral arteries three times. Children from
the HD group were examined on an intradialytic day and
children in the PD group emptied the peritoneal cavity
before measurement. PWV was assessed using a high-
fidelity tonometric probe (Miller Instruments Inc, Houston
TX, USA) connected with a recording device SphygmoCor
(AtCor Medical Pty Ltd, Sydney, Australia) and computed
with appropriate software for signal analysis (Sphygmocor
software AtCor Medical Pty Ltd, Sydney, Australia),
according to the previously described methodology [25].
The coefficient of variation between the results of measure-
ments of carotid-femoral PWV, in 4-h intervals, was 4.5 %.
All PWV examinations were performed by one examiner.
PWV values were indexed to height and presented as index
PWV/ht.
Echocardiographic measurements were performed using
a Sonos 1000 device (Hewlett Packard, NY, USA) with a
3.5-MHz sonographic probe. LVM was calculated accord-
ing to the formula of Devereux [26]. LVM was indexed to
body height according to the de Simone formula: LVMI0
LVM (g) / height (m)2.7 [27]. All echocardiograms were
stored and analyzed by one cardiologist who was blinded
to the examined children.
Skin autofluorescence was assessed using the AGE Reader
device (Diagnoptics BV, Groningen, The Netherlands), as
described previously by Meerwald et al. [28]. In brief, the
ratio of average light intensity per nanometer in the range
between 420 and 600 nm emitted by the source, divided by
the average of excited light intensity per nanometer in the
range between 300 and 420 nm was used as the measure of
autofluorescence. The intra- and inter-day coefficient of vari-
ation for autofluorescence reader measurements was 2.7 %.
sAF was expressed in arbitrary units (AU). All measurements
were performed on normal skin of the lower arm (ventral site,
about 5 cm distal to the antecubital space), at room tempera-
ture with the patient in a seated position.
Statistical analysis
The results were expressed as mean values ± standard devi-
ation when a normal distribution of variables was obtained.
The differences were then compared by ANOVA test. In the
case of non-normal distribution, a non-parametric Kruskal–
Wallis test for median values was used. For the evaluation of
the relationship between factors when normal distribution of
variables was obtained, the Pearson’s correlation test was
performed. The Spearman’s test was applied for data with
non-normal distribution. Multiple regression analysis was
performed with sAF as a dependent variable. A p value in
the ANOVA table less than 0.05 indicated a statistically
significant relationship between the variables at the 95.0 %
confidence level. Statistical analyses were performed using
the package STATGRAPHICS (Centurion XV v.15.2.06,
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StatPoint Inc, VA, USA). A p value less than 0.05 was
considered statistically significant.
Results
Table 1 describes the clinical and biochemical character-
istics of investigated CKD groups and controls with two-
by-two comparison. Examined groups were comparable for
age, gender, and BMI values. The highest values of SBP and
DBP were obtained in children on hemodialysis. They were
significantly different as compared to children in the PD,
Pre, and control groups. The mean time on PD was shorter
than maintenance HD duration.
Table 2 shows the detailed results of PWV/ht, LVM,
LVMI, sAF measurements, and homocysteine concentration
in examined groups with two by two comparison.
The values of PWV are expressed as the index PWV/ht.
The highest value of PWV/ht was obtained in the HD group
and was significantly different from other groups. PWV/ht
values were also increased in PD and Pre groups as com-
pared to controls.
sAF was significantly higher in all groups of children
with CKD compared to controls. The highest absolute sAF
values were observed in HD group, but we failed to dem-
onstrate a significant difference in comparison with the PD
group. LVM was not different between the examined
groups. LVMI showed a significant increase in all children
with CKD as compared to healthy children. The highest
values were recorded in HD and were significantly different
from results in PD and Pre groups. Homocysteine concen-
tration was significantly elevated in both groups of dialyzed
patients. The pre-dialysis CKD group was split into CKD2-
3 and CKD4-5 stages. The sAF values in the CKD 2–3
group were mean 1.72±0.41 and 2.23±0.36 in the CKD
4–5 group. Differences were significant, with p00.0007.
Analysis of factors associated with sAF
In dialyzed children (PD and HD), significant positive linear
correlations of sAF with dialysis treatment duration, P and
Ca × P were found. In children with CKD, when we ana-
lyzed all three groups (PD, HD, Pre), significant positive
correlations of sAF with LVMI, PWV/ht, SBP, DBP, P,
Ca × P and homocysteine concentration were revealed. A
negative correlation of sAF and creatinine clearance was
detected in the pre-dialysis group (p00.0003). Detailed data
are shown in Table 3, and Figs. 1 and 2.
Table 2 PWV/ht, sAF, LVM, LVMI and homocysteine values in examined groups (two-by-two comparison, p values are shown)
Group parameter PD, n020 HD, n020 Pre, n036 Controls, n026 p value
PWV/ht (m/s) 5.51±0.68a,c 6.07±0.86a,b,d 5.53±0.69a,c 4.85±0.62 p < 0.0001
sAF (10–2 AU) 2.46±0.72a,d 2.61±0.57a,d 1.9±0.46a,b,c 1.33±0.26 p < 0.0001
LVM (g) 92.5±21.9 106.2±32.3 94.2±26.7 92.3±20.5 NS
LVMI (g/m2,7) 32.9±5.5a,c,d 37±6.4a,b,d 27.3±6.6b,c 26.4±5.2 p < 0.0001
Homocysteine
(μmol/l)
14.39±1.88a,d 15.83±3.29a,d 11.24±2.74a 7.64±1.55 p < 0.0001
PWV/ht pulse wave velocity indexed to height, sAF skin autofluorescence, LVMI left ventricular mass index
a PD, HD, Pre vs. control group
b HD, Pre vs. PD
c PD, Pre vs. HD
d PD, HD vs. Pre
Table 3 Analyses of factors correlated with sAF (10–2 AU) (Pearson
correlation test)
Variable r p value
sAF (10–2AU) (PD + HD + Pre)
LVMI (g/m2,7) 0.44 0.0001
PWV/ht (m/s) 0.24 0.03
homocysteine (μmol/l) 0.26 0.02
SBP (mmHg) 0.28 0.01
DBP (mmHg) 0.23 0.03
P (mg/dl) 0.46 <0.0001
CaxP (mg2/dl2) 0.44 <0.0001
sAF (10–2AU) (PD + HD)
dial. treatment duration (months) 0.46 <0.0001
P (mg/dl) 0.33 0.03
CaxP (mg2/dl2) 0.32 0.03
sAF (10–2AU) (Pre)
Creatinine clearance (ml/min/1.73 m2) 0.42 0.0003
sAF (10–2AU) (Control)
Ca (mg/dl) 0.51 0.007
sAF skin autofluorescence, LVMI left ventricular mass index, PWV/ht
pulse wave velocity indexed to height, SBP systolic blood pressure,
DBP diastolic blood pressure
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In dialyzed children (PD, HD), a multivariate regression
analysis revealed significant positive association of sAF
with dialysis treatment duration and SBP. In the total CKD
patients (PD, HD, Pre), a significant positive association of
sAF with LVMI and P was found. The detailed data are
shown in Table 4.
Discussion
This is the first study demonstrating an elevation of sAF in
children with various stages of CKD and the relationship of
sAF with other cardiovascular risk factors, including in-
creased arterial stiffness and LVMI, hypertension, disturbed
lipid metabolism, mineral bone disease, and high homocys-
teine levels. AGEs are generated as the result of protein
glycation (Maillard reaction) under physiological conditions.
The process is more pronounced in a hyperglycemic state and
during oxidative and carbonyl stress [14]. Free circulating
AGEs are cleared from the bloodstream by glomerular filtra-
tion with subsequent reabsorption in renal tubules and further
degradation. A certain level of AGEs is not cleared and
accumulates in tissues with low turnover [29].
Patients with stage 5 CKD are particularly at risk of accu-
mulation of AGEs because of overproduction de novo as the
consequence of increased oxidative stress. On the other hand,
the clearance of AGEs precursors also decreases towards zero
[30]. Our study in children also confirmed this observation.
Increased values of sAF were documented in all groups of
examined children with CKD as compared to healthy controls.
The highest values were obtained in hemodialyzed children.
However, these were not significantly different from the val-
ues observed in children on PD. Therefore, our results are
consistent with those presented for adult CKD patients [7, 31].
Meerwald et al. [20] revealed two-fold higher values of sAF in
109 patients on HD as compared to healthy subjects. More-
over, they showed that sAF was an independent predictor of
increased cardiovascular mortality. The causes of sAF in-
crease are multifactorial and not only related to end-stage
kidney damage but also to modality of dialysis. PD, which
includes the use of glucose concentration fluids, particularly
has an influence on AGEs generation. Administration of PD
solutions with low GDP (glucose degradation products) con-
tent reduces plasma AGE levels and may improve cardiovas-
cular risk profile [32]. On the other hand, bio-incompatible
materials (i.e., dialysis membranes) in patients on hemodialy-
sis aggravate oxidative stress leading to an increase of AGEs.
It should be stressed that a single dialysis session is not
effective for removal of AGEs, and for instance 3-
deoxyglucozone is not eliminated at all [33–35]. Our multi-
variate analysis demonstrates that the duration of dialysis
treatment is an independent predictor of increased sAF.
Significantly lower values of sAF in children with CKD
treated conservatively could be explained by higher renal
clearance for AGEs and by the dietary regimen with low
protein content. However, also in this group, sAF values
were significantly higher than in the healthy control group.
This study shows that sAF gradually increases with a simul-
taneous decline of glomerular filtration. Recently, similar
results were published in an adult CKD population [36]. It
PWV/ht
3.7 4.7 5.7 6.7 7.7 8.7
0
1
2
3
4
5
sA
F
Fig. 2 Correlation between sAF and PWV/ht in all CKD children (r0
0.24; p00.03). sAF - skin autofluorescence (10–2AU), PWV/ht - pulse
wave velocity/height (m/s)
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Fig. 1 Correlation between sAF and creatinine clearance in predialysis
children (r0–0.37; p00.0003). sAF - skin autofluorescence (10–2AU),
creatinine clearance (ml/min/1.73 m2)
Table 4 Multiple regression analyses of factors associated with skin
autofluorescence (sAF)
Variable R2 β 95 % CI p value
sAF (10–2AU) (PD + HD + PRE)
LVMI (g/m2,7) 36.9 % 0.01 –0.003 –0.03 0.03
P (mg/dl) 36.9 % 0.06 –0.29 –0.41 0.02
sAF (10–2AU) (PD + HD)
dial. treatment
duration (months)
28.8 % 0.05 –0.09 to –0.01 0.02
SBP (mmHg) 28.8 % 0.08 –0.01– 0.01 0.03
LVMI left ventricular mass index, SBP systolic blood pressure, PD
peritoneal dialysis, HD hemodialysis
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should be underlined that such an association was not
found with circulating AGEs [37]. Therefore, sAF is
more a suitable method for the evaluation of AGEs
accumulation.
There are only a few manuscripts on pediatric popula-
tions with CKD that deal with the problem of AGEs. Sebe-
kova et al. [38] examined plasma concentration of AGEs
(fluorescent molecules, carboxy-methyl-lysine - CML) in a
CKD group, which was composed of 18 children on con-
servative treatment, 10 on dialysis, and 9 transplanted
patients. Increased AGEs levels were found in all children,
with the highest values in subjects on dialysis. No signifi-
cant correlation between AGEs levels and inflammatory
marker concentrations (CRP, IL-6, TNF-α) was not found.
These results are concordant with ours obtained during the
sAF evaluation, but the interpretation should be slightly
different. There is no direct correlation of sAF with circu-
lating AGEs, but only with CML [37]. Studies on the
relationship of AGEs with cardiovascular complications in
patients with stage 5 CKD showed that AGEs play a role in
the pathogenesis of vascular and cardiomyocyte alteration.
They were localized in aortic atherosclerotic plaques and
cardiomyocytes and in calcifications of coronary arteries [7,
15, 31]. Recent studies have revealed a significant correla-
tion of plasma pentosidine and atherosclerotic lesion pro-
gression, measured by changes in the carotid intima-media
complex [39]. Similar association was shown in adult
patients with cardiovascular disease without CKD [20].
There are only limited data available on sAF relationship
with cardiovascular risk factors in patients with CKD. These
studies were conducted in subjects on maintenance dialysis.
In our study the significant association of sAF and PWV/ht
was shown for the children with CKD. Similar results were
obtained by Ueno et al. [7] in a population of 120 adult
patients on hemodialysis. They confirmed that AGEs are
key factors in the pathogenesis of vascular stiffness. Vish-
vanath et al. [40] observed such a relationship in their study
on pentosidine concentration in skin specimens from
patients with type 1 diabetes. They documented a positive
correlation with pulse pressure as a measure of vascular
stiffness. In the Baltimore Longitudinal Study of Aging
(BLSA), conducted in relatively healthy, community-
dwelling adults, the results showed that serum AGEs, as
represented by CML, were associated with increased arterial
stiffness even after excluding all diabetic patients [4].
In our study population we did not detect LVM hyper-
trophy in any group, but LVMI was markedly higher in
dialyzed patients as compared to healthy children and the
conservative treatment group. It should be emphasized that
during the two-year observation study of Mitsnefes et al.,
LVMI was a predictive factor for LV hypertrophy in chil-
dren with CKD on conservative treatment [41]. Also Zocalli
et al. documented, in a large prospective study conducted in
adult patients on hemodialysis, that LVMI is an unfavorable
predictor of cardiovascular events [42].
In this current study, we describe for the first time that
sAF positively correlates with LVMI in a group of children
with CKD. This confirms the role of AGEs in the pathogen-
esis of cardiac myocyte alteration. It is also possible that the
impact of AGEs is indirect, mediated by their influence on
vascular alteration. The positive correlation between PWV/
ht and LVMI in children with CKD (R00.32; p00.003)
supports this hypothesis. We discovered a close relationship
of sAF with blood pressure values, which is consistent with
the results of a Japanese group [43].
In this study, we analyzed, for the first time, the associ-
ation of tissue AGEs with hyperhomocysteinemia, which is
a known cause of endothelium damage [44, 45]. We docu-
mented that sAF shows a strong correlation with homocys-
teine in children with CKD. Similar association was found
with classical risk factors, such as serum phosphate and
calcium-phosphorus product. The influence of hyperphos-
phatemia, hypercalcemia, and high values of calcium-
phosphorus product on the progression of vascular calcifi-
cation and stiffening of vascular wall has been previously
documented.
Our study has several limitations. Firstly, the sample size,
particularly in subgroups, may be insufficient to show sta-
tistical differences. One should emphasize that the pediatric
population with CKD is markedly smaller as compared to
the population of adult patients with CKD. The epidemio-
logical data estimate that children with stage 5 CKD account
for only 2 % of the corresponding adult population [46]. Our
patients were recruited from the three nephrological centers
for children, which treat patients from the whole south
region of our country.
Future studies with larger sample sizes are necessary,
especially in the light of new therapeutic possibilities, which
are responsible for the lowering of AGEs. These animal
experiments have documented that some AGE cross-link
breakers may prevent alterations in vessels and heart myo-
cytes [47, 48]. Lewis et al. suggest that patients with less-
advanced stages of CKD might benefit received pyridox-
amine that might inhibit the formation of AGEs [49].
In summary, our study showed for the first time that in
children with CKD, sAF, as a measure of tissue AGEs
accumulation, is elevated simultaneously with GFR decline.
The highest values of sAF were detected in patients on
maintenance dialysis, probably due to further increases of
oxidative stress related to the dialysis procedure. As sAF
was associated with early cardiovascular changes and some
biochemical CVD risk factors, our study supports the clin-
ical association of AGEs with development of cardiovascu-
lar complications. Therefore, sAF as a non-invasive method
may be a useful tool for assessment of CVD risk factors in
children with CKD.
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